Updated 15 November 2026. Germany’s rapid cannabis market growth primarily concerns medical products. BfArM data show around 205.1 tonnes of dried flower imported for medical and medical-scientific purposes in 2025, compared with about 72.9 tonnes in 2024. This is import data, rather than total consumption or pharmacy sales. Our medical cannabis guide explains separate prescription and reimbursement rules.
Two systems: medical cannabis and personal use
Germany’s 2024 reform involved distinct areas. Medical cannabis is dispensed on prescription by pharmacies under a separate law. Limited personal cultivation and non-profit associations are permitted for non-medical adult use.
The reform did not authorise an ordinary nationwide recreational retail market. Associations are not conventional shops: they may distribute cannabis grown under the statutory conditions to their adult members.

Why did the medical market grow?
Import growth accompanied expansion of the prescription market and supply changes. BfArM’s quarterly chart, checked on 15 November 2026, totals 205,107 kg of dried flower for 2025, around 205.1 tonnes. The 2024 quarters total 72,850 kg, around 72.9 tonnes, making the annual volume roughly 2.8 times larger. A 201.1-tonne figure in specialist reporting from March 2026 reflects older data; BfArM revises figures as late notifications arrive.
The chart covers dried flowers, rather than every preparation, extract or prescription. Imports alone do not establish the quantity sold to end users that year. Some stock may remain in storage, move onward or be used scientifically. Patient and revenue estimates also vary by source and method.
What is permitted for personal adult use?
The Federal Health Ministry describes up to three plants per adult for personal cultivation, with possession limits of 25 grams in public and 50 grams of dried cannabis at home. Associations have separate membership, quantity and oversight rules.
Ordinary retail sales, online sales and delivery were not generally permitted by this reform. Public use also remains significantly restricted.
Has the illicit market shrunk?
That cannot be concluded from pharmacy import volumes alone. Evaluation requires separate evidence about illicit sales, purchasing channels and enforcement. Germany’s official reform evaluation also produced interim reports in 2025 and 2026.
Market growth by itself therefore does not prove a substantial reduction in illicit trade or achievement of every reform goal.
What does this mean for Europe?
Germany illustrates that expanding prescription access and permitting limited personal cultivation are different policy steps. Import growth describes healthcare and pharmaceutical supply, rather than unrestricted recreational retail legalisation.
